<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00184054</url>
  </required_header>
  <id_info>
    <org_study_id>9L-02-1</org_study_id>
    <nct_id>NCT00184054</nct_id>
  </id_info>
  <brief_title>Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia</brief_title>
  <official_title>Phase II Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-APL Acute Myelogenous Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <brief_summary>
    <textblock>
      This clinical research study is for patients with acute myelogenous leukemia (in short AML)
      that did not respond to previous treatment or unable to receive chemotherapy.

      Arsenic has been used as a drug for many centuries. While arsenic containing drugs were used
      in the past for cancer treatments, the major use of arsenic in western countries has been for
      the treatment of uncommon tropical illnesses, such as sleeping sickness. Recently, some new
      information suggests that arsenic in a form called arsenic trioxide may also be useful to
      treat some cancers of the blood, such as leukemia, lymphoma and myeloma. Studies from China
      and the USA showed that patients with a type of blood cancer called acute promyelocytic
      leukemia, whose disease failed to respond to other treatments, responded very well to arsenic
      trioxide. Studies done in laboratories in the United States have shown that arsenic can kill
      AML cells growing in culture dishes.

      Ascorbic acid (vitamin C), a natural supplement in our diet, has long been involved with
      cancer prevention. Laboratory tests have shown that although arsenic trioxide by itself can
      kill AML cells in the test tube, when vitamin C is added to arsenic trioxide in a test tube,
      the death of the leukemia cells increases significantly.

      The purpose of this study is to find out if the combination of arsenic trioxide (Trisenox)
      and ascorbic acid is effective in the treatment of patients who have AML. The second purpose
      is to study how the two drugs affect cells in the laboratory. Samples from the blood and bone
      marrow (the part of the body that makes blood cells) will be collected, at specific times
      during treatment, in order to study them in the laboratory. By studying blood and marrow
      cells, researchers hope to learn the mechanisms by which the drugs work.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Competing studies
  </why_stopped>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Response (Complete Remissions (CR) and Complete Remission With Incomplete Blood Count Recovery (CRi)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Complete Remission (CR): ANC &gt;=1000/mcl, Platelet count &gt;=100,000/mcl, Bone marrow &lt;5% blasts. Complete Remission with incomplete blood count recovery (CRi): Same as CR but ANC may be &lt;1,000/mcl and/or platelet count &lt;100,000/mcl. Patients who failed to achieve CR or CRi after two cycles were considered treatment failures. Patients who did not complete at least two cycles were not evaluated for response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe (Grades 3-5) Adverse Events</measure>
    <time_frame>Days 1, 8, 15, 21, 28, 35 of each cycle and at end of treatment (30 days after last dose or start of new therapy)</time_frame>
    <description>Patients who received any amount of ATO plus Ascorbic Acid are included in the safety analyses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Arsenic Trioxide (ATO) Plus Ascorbic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arsenic Trioxide (ATO) given at 0.25 mg/kg/day intravenously for 25 days over a 35-day period.
Ascorbic Acid given at 1000 mg/day intravenously every other day that ATO is given</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide (ATO)</intervention_name>
    <description>Arsenic Trioxide .25 mg/kg/day</description>
    <arm_group_label>Arsenic Trioxide (ATO) Plus Ascorbic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Ascorbic Acid 1000 mg every other day for 25 days</description>
    <arm_group_label>Arsenic Trioxide (ATO) Plus Ascorbic acid</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non-APL AML (FAB subtypes M0 - M7 but excluding M3) confirmed by
             myeloperoxidase stain and/or flow cytometry.

          -  For patients of age 18 or older - only refractory or relapsed AML will be included.
             Refractory disease is defined as newly diagnosed patients who fulfill ONE of the
             following criteria:

               -  Patient aged 60 years or younger, who have failed to achieve a complete remission
                  after at least two cycles of front line induction chemotherapy.

               -  Patients of any age who have AML, that is post myelodysplastic syndrome (MDS),
                  who failed to achieve a complete remission after at least one cycle of front line
                  induction chemotherapy.

               -  Patients aged 60 years or older who failed to achieve a complete remission after
                  at least one cycle of front line induction chemotherapy.

          -  Newly diagnosed patients aged 55 or older who will not receive intensive anti-leukemia
             chemotherapy can also be enrolled.

          -  Post-myelodysplasia AML and secondary AML are included.

          -  Stem cell transplantation failures are included.

          -  Karnofsky performance status greater or equal to 50%.

          -  Adequate renal function (creatinine &lt; 1.5 x ULN or creatinine clearance &gt; 60 ml/min)
             and hepatic function (transaminases &lt; 2.5 x ULN, serum total bilirubin &lt; 3 mg/dl).

          -  Females of childbearing potential must have a negative serum pregnancy test prior to
             enrollment on the study, and both women and men must use an effective birth control
             method while on the study.

          -  Signed consent.

        Exclusion Criteria:

          -  Newly diagnosed patients older than age 55 who:

               -  Refuse chemotherapy when their treating physician recommends standard
                  anti-leukemia induction chemotherapy.

               -  Have a Karnofsky performance status of greater or equal to 70%, aged &lt; 75 years
                  and has no prior myelodysplastic syndrome.

               -  Have a risk/benefit ratio that gives their treating physician good reason for
                  administration of standard anti-leukemia induction chemotherapy.

          -  Patients who have already been treated with arsenics.

          -  CML in blastic crisis.

          -  Patients with cardiopathies including recurrent supraventricular arrhythmia and any
             type of sustained ventricular arrhythmia or conduction block (A-V block grade II or
             III, LBBB).

          -  Patients with HIV.

          -  Pregnant or breastfeeding women.

          -  QT interval &gt; 460 msec in the presence of serum potassium &gt; 4.0 mEq/L and magnesium &gt;
             1.8 mg/dL.

          -  Pre-existing neurotoxicity/neuropathy of Grade 2 or greater according to the NCI
             Common Toxicity Criteria Version 2.

          -  History of preexisting neurological disorders (grade 3 or higher by the NCI Common
             Toxicity Criteria; in particular, seizure disorders).

          -  Patients with an underlying medical condition that could be aggravated by the
             treatment or life threatening disease unrelated to AML as evaluated by the enrolling
             physician.

          -  Patients with active second malignancy, excluding adequately treated basal or squamous
             cell carcinoma of the skin, or carcinoma in situ of the cervix.

          -  Inability or unwillingness to comply with the treatment protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Douer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center and Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>June 13, 2014</results_first_submitted>
  <results_first_submitted_qc>June 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 17, 2014</results_first_posted>
  <last_update_submitted>July 16, 2014</last_update_submitted>
  <last_update_submitted_qc>July 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Arsenic trioxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for this study opened in April 2002 and closed in May 2008. All subjects were seen at USC.</recruitment_details>
      <pre_assignment_details>The study has no pre-assignment. All subjects were given the same treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arsenic Trioxide (ATO) Plus Ascorbic Acid</title>
          <description>All subjects received ATO 0.25 mg/kg/day intravenously for 25 days over a 35-day period and Ascorbic Acid 1000 mg/day intravenously every other day that ATO is given</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants were included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Arsenic Trioxide (ATO) Plus Ascorbic Acid</title>
          <description>All subjects received ATO 0.25 mg/kg/day intravenously for 25 days over a 35-day period and Ascorbic Acid 1000 mg/day intravenously every other day that ATO is given</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Response (Complete Remissions (CR) and Complete Remission With Incomplete Blood Count Recovery (CRi)</title>
        <description>Complete Remission (CR): ANC &gt;=1000/mcl, Platelet count &gt;=100,000/mcl, Bone marrow &lt;5% blasts. Complete Remission with incomplete blood count recovery (CRi): Same as CR but ANC may be &lt;1,000/mcl and/or platelet count &lt;100,000/mcl. Patients who failed to achieve CR or CRi after two cycles were considered treatment failures. Patients who did not complete at least two cycles were not evaluated for response.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>All subjects who received at least 2 cycles of treatment as part of this study are included in the analysis of response.</population>
        <group_list>
          <group group_id="O1">
            <title>Arsenic Trioxide (ATO) Plus Ascorbic Acid</title>
            <description>All subjects received ATO 0.25 mg/kg/day intravenously for 25 days over a 35-day period and Ascorbic Acid 1000 mg/day intravenously every other day that ATO is given</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Response (Complete Remissions (CR) and Complete Remission With Incomplete Blood Count Recovery (CRi)</title>
          <description>Complete Remission (CR): ANC &gt;=1000/mcl, Platelet count &gt;=100,000/mcl, Bone marrow &lt;5% blasts. Complete Remission with incomplete blood count recovery (CRi): Same as CR but ANC may be &lt;1,000/mcl and/or platelet count &lt;100,000/mcl. Patients who failed to achieve CR or CRi after two cycles were considered treatment failures. Patients who did not complete at least two cycles were not evaluated for response.</description>
          <population>All subjects who received at least 2 cycles of treatment as part of this study are included in the analysis of response.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRi</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Evaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe (Grades 3-5) Adverse Events</title>
        <description>Patients who received any amount of ATO plus Ascorbic Acid are included in the safety analyses.</description>
        <time_frame>Days 1, 8, 15, 21, 28, 35 of each cycle and at end of treatment (30 days after last dose or start of new therapy)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arsenic Trioxide (ATO) Plus Ascorbic Acid</title>
            <description>All subjects received ATO 0.25 mg/kg/day intravenously for 25 days over a 35-day period and Ascorbic Acid 1000 mg/day intravenously every other day that ATO is given</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe (Grades 3-5) Adverse Events</title>
          <description>Patients who received any amount of ATO plus Ascorbic Acid are included in the safety analyses.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conjunctivitis infective</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Differentiation syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Electrocardiogram QT corrected interval prolonged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neuropathy: sensory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Days 1, 8, 15, 21, 28, 35 of each cycle and at end of treatment (30 days after last dose or start of new therapy)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arsenic Trioxide (ATO) Plus Ascorbic Acid</title>
          <description>All subjects received ATO 0.25 mg/kg/day intravenously for 25 days over a 35-day period and Ascorbic Acid 1000 mg/day intravenously every other day that ATO is given</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Differentiation syndrome</sub_title>
                <description>Shortness of breath with hypoxia responding to steroids during hyperleukocytosi</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy sensory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis - hand</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Victoria Soto, Project Specialist, Clinical Investigations Support Office</name_or_title>
      <organization>USC Norris Comprehensive Cancer Center</organization>
      <phone>323-226-6384</phone>
      <email>victoria.soto@med.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

